Plasma CXCL9 elevations correlate with chronic GVHD diagnosis
Open Access
- 30 January 2014
- journal article
- Published by American Society of Hematology in Blood
- Vol. 123 (5), 786-793
- https://doi.org/10.1182/blood-2013-08-520072
Abstract
Key Points Plasma concentrations of CXCL9 are elevated at the onset of cGVHD diagnosis, but not in patients with cGVHD for more than 3 months. Plasma concentrations of CXCL9 are impacted by immunosuppressive therapy.Keywords
This publication has 29 references indexed in Scilit:
- Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host diseaseBlood, 2011
- Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host diseaseBlood, 2011
- Elafin Is a Biomarker of Graft-Versus-Host Disease of the SkinScience Translational Medicine, 2010
- Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donorsBlood, 2009
- Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host diseaseBlood, 2009
- Increased T-bet+ cytotoxic effectors and type I interferon–mediated processes in chronic graft-versus-host disease of the oral mucosaBlood, 2009
- A biomarker panel for acute graft-versus-host diseaseBlood, 2009
- Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology GroupBlood, 2008
- Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host diseaseBlood, 2008
- High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host DiseaseClinical Cancer Research, 2007